Is Celularity going out of business?

Celularity Inc. (CELU) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Celularity Inc. (CELU) scores 22 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)

Five questions, kept separate

Survival - Critical

3-5 mo of estimated runway from 2025-12-31, based on $6.2M of cash and short-term investments against $20.2M of annual burn. Adjusted shares outstanding increased 27.9% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

-126.2% net-cash backing support an extreme expectations pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Interest coverage: -1703.0x
• Revenue CAGR (3Y): 13.88%
• Shares dilution YoY: 27.90% (YoY)
• R&D intensity: 43.98%
• Revenue growth YoY: -77.37% (YoY)
• Return on Assets: -85.45%
• Debt Maturity Runway: 100% long-term (Long-term focused)
• Price / Sales: 1.6x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -946.7%
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-04-30.

Price as of 2026-09-07.